Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung17: Datopotamab deruxtecan vs docetaxel in previously treated TROP2-positive advanced non-squamous NSCLC
2024-520101-39-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival (PFS) by BICR per RECIST v1.1 and Overall survival (OS). Planned start Apr 2026; status: authorised.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-520101-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520101-39-00.